The Next Generation of Dermal Fillers: A Focus on Regeneration and Skin Quality
Aesthetic medicine is evolving with the introduction of mesofiller® nexha, focusing on skin quality and regeneration rather than just volumetric correction.
The Next Generation of Dermal Fillers: A Focus on Regeneration and Skin Quality
- 18th May 2026
- Thierry PIOLATTO
Dr Íñigo De Felipe Speaker at the mesoestetic® symposium, IMCAS and AMWC.
As the field of aesthetic medicine advances, there is a notable shift from traditional volumetric enhancements to approaches that emphasize skin quality and long-term dermal health. The introduction of the second generation of mesofiller® nexha marks a significant development in this trend, showcasing a blend of immediate structural correction with innovative mechanisms aimed at fostering ongoing dermal regeneration.
Dr. Íñigo De Felipe, a prominent dermatologist and speaker at the recent mesoestetic® symposium during IMCAS Paris 2026, discusses how this new formulation aligns with the evolving philosophy of aesthetic treatments.
In recent years, there has been a growing conversation about transitioning from solely corrective treatments to those that enhance skin quality and promote regeneration. How do you perceive this shift in clinical practice? Dr De Felipe: Skin quality is essential. Factors like luminosity, texture, and dermal density significantly influence facial perception. The second generation of mesofiller® nexha is well-suited to this evolution, integrating correction with biological elements that support skin activity over time.
What makes the formulation of this second generation of mesofiller® nexha particularly compelling from a clinical perspective? Dr De Felipe: A notable feature is the synergy of cross-linked hyaluronic acid with succinic acid and specific active ingredients tailored for various indications. Hyaluronic acid provides the expected structural benefits of a filler for immediate correction, while succinic acid is linked to cellular metabolic functions and may enhance fibroblast activity.
Moreover, this generation includes unique ingredient combinations designed for specific clinical needs, improving the treatment's effectiveness in addressing diverse concerns.
In practical terms, this means that the treatment not only offers immediate aesthetic enhancements but may also lead to gradual improvements in skin quality, such as enhanced texture and luminosity over time.
As more clinicians explore regenerative strategies in aesthetic medicine, do you foresee innovations like this reshaping the future use of fillers? Dr De Felipe: Absolutely. The focus is shifting from merely correcting visible signs of aging to considering how treatments can also support the skin's biological functions. Products that merge structural correction with biostimulation present exciting possibilities.
Additionally, we are witnessing a trend toward combination therapies, where multiple procedures are integrated to provide a holistic, 360-degree approach to patient care, rather than relying on a single technique.
In this context, the second generation of mesofiller® nexha embodies a broader movement in aesthetic medicine that seeks to achieve natural-looking results while working harmoniously with the skin's biology over time.
